Delving into the Latest Updates on Human papillomavirus vaccine [types 16, 18](GlaxoSmithKline Plc) with Synapse

This phase IV trial tests whether a single dose of the human papillomavirus (HPV) vaccine works in preventing cervical cancer in young women in Costa Rica. Human papilloma viruses, called HPV, are a group of viruses that very frequently cause infection in both men and women, mainly in the genital organs. There are many types of HPV, and some can cause cancer. The World Health Organization recommends a two-dose schedule for adolescents 9-14 and three doses for individuals 15 years old or older. This study examines whether a single dose of HPV vaccine can reduce the frequency with which women between ages 18-30 become infected with HPV.

Start Date01 Mar 2022

Sponsor / Collaborator

National Cancer Institute

NCT04301154 / Active, not recruitingPhase 1IIT

Phase I, Proof of Concept, Open-Label, Randomized Clinical Trial to Evaluate the Safety and Effects of Using Prime-boost HIVIS DNA and MVA-CMDR Vaccine Regimens With or Without Toll-like Receptor 4 Agonist on HIV Reservoirs in Perinatally HIV Infected Children and Youth

Phase I, Proof of Concept, Open-Label, Randomized Clinical Trial to Evaluate the Safety and Effects of Using Prime-boost HIVIS DNA and MVA-CMDR Vaccine Regimens with or without Toll-like Receptor 4 Agonist on HIV Reservoirs in Perinatally HIV Infected Children and Youth

Start Date18 Feb 2022

Sponsor / Collaborator

The Henry M. Jackson Foundation

[+11]

CTR20210523 / CompletedPhase 4

一项监测葛兰素史克生物制品公司希瑞适疫苗上市前后依据当地处方信息接种希瑞适疫苗的9-45岁中国女性安全性相关终点的观察性数据库研究。

[Translation] An observational database study monitoring safety-related endpoints in Chinese women aged 9-45 years who received GlaxoSmithKline Biologicals' Cervarix vaccine according to local prescribing information before and after its launch.

第1步：评估数据库中识别安全性相关终点的性能（次要目的）：针对所关注的潜在免疫介导疾病（pIMD）和妊娠结局，评估病例识别方法的准确性。第2步：基线分析（次要目的）：估算上市前观察期9~45岁女性pIMD发病率，包括每个日历年的总体与年龄别发病率。估算上市前观察期9~45岁怀孕女性中妊娠结局发病率，包括每个日历年的总体与年龄别发病率。估算9~45岁女性希瑞适疫苗接种率，包括每个日历年的总体与年龄别接种率。第3步：主要分析（主要目的）：估算上市前和上市后观察期间，9~45岁女性可识别的最常见的pIMD的发病率，包括每个日历年的总体与年龄别发病率。估算上前和上市后观察期间9~45岁妊娠女性中可识别的妊娠结局的发病率，包括每个日历年的总体与年龄别发病率。第4步：条件性分析（次要目的）：以疫苗接种率和实际观察的发病率为前提条件，评估上市前、后在接种和未接种希瑞适疫苗的人群中，疫苗接种后12个月内发生可识别的最常见的pIMD的可能性。以疫苗接种率和实际观察的发病率为前提条件，评估上市前、后在接种和未接种希瑞适疫苗的人群中，疫苗接种后发生可识别的妊娠结局的可能性。

[Translation]

Step 1: Evaluate the performance of identifying safety-related endpoints in the database (secondary objective): Evaluate the accuracy of the case identification method for potential immune-mediated diseases (pIMDs) and pregnancy outcomes of interest. Step 2: Baseline analysis (secondary objective): Estimate the incidence of pIMDs in women aged 9 to 45 years during the pre-marketing observation period, including overall and age-specific incidence rates for each calendar year. Estimate the incidence of pregnancy outcomes in pregnant women aged 9 to 45 years during the pre-marketing observation period, including overall and age-specific incidence rates for each calendar year. Estimate the vaccination rate of Cervarix in women aged 9 to 45 years, including overall and age-specific vaccination rates for each calendar year. Step 3: Primary analysis (primary objective): Estimate the incidence of the most common pIMDs that can be identified in women aged 9 to 45 years during the pre-marketing and post-marketing observation periods, including overall and age-specific incidence rates for each calendar year. Estimate the incidence of identifiable pregnancy outcomes in pregnant women aged 9 to 45 years during the pre-marketing and post-marketing observation periods, including overall and age-specific incidence rates for each calendar year. Step 4: Conditional analysis (secondary objective): To assess the likelihood of identifiable pregnancy outcomes occurring within 12 months after vaccination in the pre- and post-marketing population with and without Cervarix, conditioned on vaccination coverage and observed incidence. To assess the likelihood of identifiable pregnancy outcomes occurring within 12 months after vaccination in the pre- and post-marketing population with and without Cervarix, conditioned on vaccination coverage and observed incidence.

Start Date10 Sep 2021

Sponsor / Collaborator

GlaxoSmithKline (China) Investment Co., Ltd.

[+1]

100 Clinical Results associated with Human papillomavirus vaccine [types 16, 18](GlaxoSmithKline Plc)

Login to view more data

100 Translational Medicine associated with Human papillomavirus vaccine [types 16, 18](GlaxoSmithKline Plc)

Login to view more data

100 Patents (Medical) associated with Human papillomavirus vaccine [types 16, 18](GlaxoSmithKline Plc)

Login to view more data

346

Literatures (Medical) associated with Human papillomavirus vaccine [types 16, 18](GlaxoSmithKline Plc)

31 Dec 2024·Human Vaccines & Immunotherapeutics

Effectiveness of HPV vaccine as part of national immunization program for preventing HPV infection in Thai schoolgirls after seven years post-vaccination

Article

Author: Wanlapakorn, Nasamon ; Nilyanimit, Pornjarim ; Aeemchinda, Ratchadawan ; Poovorawan, Yong ; Suntronwong, Nungruthai ; Seetho, Sunanta ; Netthip, Naiyana ; Bhunyakitikorn, Wichan ; Phosri, Darunee ; Vichaiwattana, Preeyaporn ; Thantithaveewat, Thanawadee

Thailand introduced a two-dose regimen of bivalent HPV vaccines for Grade 5 schoolgirls, approximately 11 years old, initially piloted in Ayutthaya province in 2014, and nationwide under the National Immunization Program (NIP) in 2017. This cross-sectional, case-control study evaluated the vaccine effectiveness in schoolgirls 7 years after a two-dose administration. Between May and June 2023, 211 grade 12 female students from Ayutthaya, who received the two-dose bivalent HPV vaccine CERVARIX^Ⓡ (HPV types 16 and 18), and 376 grade 12 students from Nakhon Pathom who did not receive the HPV vaccine, were enrolled. HPV infection was detected by testing for HPV DNA in the first-void urine samples using real-time PCR (Cobas® 4800 and Anyplex^TM HPV28). The study found that the HPV vaccine 100% effective against high-risk HPV (HR-HPV) types included in the vaccine (16, 18) and 32.8% effective against other HR-HPV types not included in the vaccine. Our findings indicated that the bivalent HPV vaccine does not provide cross-protection against non-vaccine HPV types. Prioritizing vaccines with the highest coverage of HR-HPV types, such as the nonavalent HPV vaccine, is crucial to effectively prevent a broader range of HR-HPV infections under the NIP.

10 Nov 2024·West African journal of medicine

KNOWLEDGE AND PERCEPTION OF HUMAN PAPILLOMAVIRUS VACCINE AMONG ADOLESCENTS AND CAREGIVERS IN JOS METROPOLIS, PLATEAU STATE, NIGERIA.

Article

Author: Tony-Okeke, T O ; Aule, S K ; Mathew, M ; Odoh, A F ; Zoakah, J H ; Nnorom, O C ; Envuladu, E A

Introduction:

HPV infection is well-recognized as a cause of nearly all cases of cervical cancer. There are currently three prophylactic HPV vaccines; a bivalent (Cervarix), a quadrivalent (Gardasil), and a nonavalent vaccine (Gardasil- 9). With the recent rollout of HPV vaccines in Nigeria, it is imperative to understand potential barriers and facilitators to its uptake.

Objectives:

The objectives of this study were to evaluate the awareness, perception, and willingness to accept HPV vaccine and explore enablers and barriers to HPV vaccine uptake among adolescents and caregivers.

Methods:

Four focus group discussions were conducted with adolescents from public and private secondary schools in Plateau, 4 with the parents of adolescents, and one IDI with the head of ANCOPSS. Each FGD had between 8-12 participants. Interviews were recorded and notes were taken. The interviews were transcribed, codes were generated and analysis was conducted using a thematic framework approach with NVIVO version 11 software.

Results:

Most participants demonstrated inadequate knowledge and poor perception of HPV and the vaccine. Girls were willing to accept the vaccine, while boys saw it as a female problem. Parents had limited knowledge but expressed willingness to allow their children to be vaccinated. The fear of side effects, poor vaccine quality, and lack of parental approval were major barriers expressed by the girls while myths and misconceptions regarding the vaccine interference with fertility and as a means of population control were significant barriers on the parts of the parents.

Conclusion:

Low awareness and poor perception of HPV vaccine exist among adolescents and caregivers. Long-term individual and community-level interventions are needed to provide accurate information address knowledge gaps and promote inclusive access.

08 May 2024·Cureus Journal of Medical Science

A Study to Assess the Impact of Education on the Knowledge and Attitude Toward Cervical Cancer and HPV (Human Papillomavirus) Vaccination Among Female Healthcare Students

Article

Author: Arjaria, Vibha ; Singh, Devendra ; Verma, Ishan ; Gavli, Jai ; Garg, Lekhraj ; Khare, Apurva ; Mungad, Ayushi ; Bajpai, Rashmi

Background Cervical cancer ranks among the top five cancers in India, with human papillomavirus (HPV) types 16 and 18 causing up to 70% of related lesions. HPV infection, acquired through various routes, poses risks for both men and women, especially in the age group of 16 to 25 years. Effective prevention is possible through HPV vaccination, with Cervarix and Gardasil approved for use in India. Despite its proven efficacy, HPV vaccine use remains minimal. This study aims to evaluate awareness, willingness, and barriers among female healthcare students while assessing the impact of a health education program on their knowledge and attitude. Methods The present study is an educational interventional study conducted on 489 female students in the healthcare sector in the age group of 19-25 years. Two questionnaires (pre-lecture and post-lecture) were used. After the pre-lecture questionnaire, a session on cervical cancer and vaccine education was delivered by the subject expert. Afterward, the post-lecture questionnaire was given and the impact of session was analyzed using various statistical tools. Result A total of 489 students across MBBS (Bachelor of Medicine, Bachelor of Surgery), BAMS (Bachelor of Ayurvedic Medicine and Surgery), BHMS (Bachelor of Homoeopathic Medicine and Surgery), paramedical, and nursing courses participated in the study. Prior to the lecture, knowledge regarding cervical cancer and vaccines was generally low across subgroups, witnessing improvements ranging from 60% to 100% in various questionnaire sections post-education. Understanding of the importance of a Pap smear (Papanicolaou test) increased significantly from 21% to 79% after the educational session. The most preferred measure to boost coverage was the inclusion of the HPV vaccine in the National Immunization Schedule, with lack of awareness identified as the most significant barrier. Conclusion An educational session not only enhances knowledge but also boosts willingness for cervical cancer vaccination. Inclusion of the vaccine in the National Immunization Schedule not only increases acceptability but also indirectly raises awareness.

13

News (Medical) associated with Human papillomavirus vaccine [types 16, 18](GlaxoSmithKline Plc)

02 Dec 2024

·www.drugs.com

Cervical Cancer Deaths Fell Dramatically After Advent of HPV Vaccine

MONDAY, Dec. 2, 2024 -- A new study provides good evidence that the human papillomavirus (HPV) vaccine may be achieving its goal of slashing rates of cervical cancer. “We observed a … 62% drop in cervical cancer deaths over the last decade, likely due to HPV vaccination,” said study senior author Ashish Deshmukh . “We cannot think of any other reason that would have contributed to such a marked decline.” Deshmukh is co-leader of the Cancer Prevention and Control Research Program at the Medical University of South Carolina's Hollings Cancer Center. HPV, a common sexually transmitted infection, is thought to cause the vast majority of cervical cancer cases. First introduced and approved in the United States in 2006, HPV vaccines such as Gardasi l and Cervarix have revolutionized cervical cancer prevention and care. It takes time to see vaccination translated into real world outcomes, such as a decline in cancer deaths. But studies focused on earlier markers -- HPV infection, precancer and new cases of cervical cancer -- had suggested that widespread vaccination among adolescents and young women might be having an impact. The new study tracked U.S. deaths among women under the age of 25 from the beginning of the 1990s through 2021. Such deaths at a very young age are rare, but Deshmukh and colleagues said that tracking them is a good indicator of whether vaccines might be working. They pointed out that in 2021, women who were 25 would have been 10 years old in 2006, when the vaccine was first introduced. The U.S. Centers for Disease Control and Prevention recommends that HPV vaccines be given to adolescents at ages 11 to 12, before the typical start of sexual activity. The team found that between 50 and 60 women under the age of 25 died of cervical cancer during every three-year block of time throughout the 1990s. However, between 2019 and 2021, that rate had fallen by nearly two-thirds, to 13 deaths over those three years. Of course, girls and women can only be protected by the HPV vaccine if they are immunized, Deshmukh said. The CDC has set a goal of an 80% vaccination rate, but its data for 2024 show that only about 60% of 13-to -15-year-olds have received the recommended doses. “There has been a decline in HPV vaccination post COVID-19 in the most recent generation of U.S. adolescent," Deshmukh said in a university news release. "This is troubling, as a decline in vaccination uptake would potentially lead to smaller gains [against cervical cancer]." The findings were published Nov. 27 in the Journal of the American Medical Association. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

VaccineDrug Approval

31 Jul 2024

·www.fiercebiotech.com

GSK drops phase 2 HPV vaccine over lack of best-in-class potential

GSK CEO Emma Walmsley told Fierce Biotech that the company is still “keeping an eye on the opportunity in HPV.” GSK has scrapped a phase 2 human papillomavirus (HPV) vaccine from its pipeline after deciding the asset wouldn’t have best-in-class potential.The British Big Pharma—which still markets the HPV vaccine Cervarix in various countries—announced the decision to remove an adjuvanted recombinant protein vaccine for the viral infection, dubbed GSK4106647, from its phase 2 pipeline as part of second-quarter earnings results (PDF).On a call with journalists this morning, CEO Emma Walmsley told Fierce Biotech that while GSK is still “keeping an eye on the opportunity in HPV, for sure,” the company has decided it doesn’t want to pursue GSK4106647 further.“One of the most important things you can do when developing a pipeline is focus on the big bets of new and differentiated assets,” Walmsley said. “And part of that means switching off things where we don't think we can necessarily cut through with something that can be a best in class.”When it comes to GSK’s vaccines portfolio more generally, the company is “doubling down both on mRNA and on our new MAPS technology,” the CEO added. Earlier this month, the Big Pharma paid CureVac $430 million for the full rights to the mRNA specialist’s flu and COVID vaccines. “The key point is: Can you bring something that's new and different and better, where there's material unmet need, and we can demonstrate differentiated value,” she added.GSK still markets the recombinant HPV vaccine Cervarix in various countries around the world. Despite pulling the vaccine from the U.S. in 2016 due to low demand, the company still saw £120 million ($154 million) in global revenue for the shot in 2023.One other drug was removed from GSK’s pipeline this morning: a proteasome inhibitor for a tropical disease called visceral leishmaniasis. Walmsley stressed on the same call that GSK has a “long-term commitment to neglected tropical diseases,” but said the decision to end work on this specific asset was a result of “the discipline of betting where we can win.”

VaccinePhase 2Clinical ResultmRNA

11 Jul 2024

·pmlive.com

WHO publishes guidance for HPV vaccine developers to help tackle cervical cancer

The World Health Organization (WHO) has published a new report to guide vaccine developers when creating innovative vaccines to treat human papillomavirus (HPV) infections in adults. Currently the main cause of cervical cancer – the fourth most common cancer in women globally – HPV is a very common group of viruses that leads to cervical cancer in more than nine out of every ten cases. Despite already-existing WHO-prequalified vaccines, including Merck & Co’s – known as MSD outside the US and Canada – Gardasil 9 (HPV 9-valent, recombinant) and GSK’s Cervarix (HPV bivalent (types 16, 18) vaccine, recombinant), to prevent HPV infections, there are currently no vaccines that can treat them. However, new therapeutic vaccines are being developed using the latest immunotherapy advances to clear HPV or treat precancerous cells in people already exposed to the virus. The WHO Preferred Product Characteristics for Therapeutic HPV Vaccines report calls on developers and outlines how they can ensure that their products meet global public health needs and how to quickly roll out vaccines if approved, while considering medical indications for potential use of such a vaccine, target populations, safety and efficacy criteria, as well as practical considerations such as delivery strategy, storage and dosage schedules, and affordability. Currently, there are more than 20 therapeutic HPV vaccine candidates that are at different stages of development, with several in clinical trials, that are likely to be most beneficial for adult women who did not receive the HPV vaccination prior to contracting the virus. In addition, these new potential therapeutic vaccines align with WHO’s Cervical Cancer Elimination Initiative, which aims to vaccinate 90% of girls with preventive HPV vaccines, screen 70% of women with a high-performance test and treat 90% of women who have precancerous cells in the cervix or cervical cancer by 2030. Dr Sami Gottlieb, medical doctor and epidemiologist, department of sexual and reproductive health and research, WHO, commented: “Therapeutic HPV vaccines could be a catalytic innovation to complement these efforts, increasing options for the millions of women who have already acquired HPV and reducing their risks of developing life-threatening cancer in the future.”

VaccineImmunotherapyClinical Study

100 Deals associated with Human papillomavirus vaccine [types 16, 18](GlaxoSmithKline Plc)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J07BM02	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Cervical Adenocarcinoma In Situ	US	GlaxoSmithKline LLC	16 Oct 2009
Uterine Cervical Cancer	US	GlaxoSmithKline LLC	16 Oct 2009
Uterine Cervical Cancer	JP	GlaxoSmithKline KK	16 Oct 2009
Uterine Cervical Dysplasia	US	GlaxoSmithKline LLC	16 Oct 2009
Anus Neoplasms	EU	GlaxoSmithKline Biologicals SA	20 Sep 2007
Anus Neoplasms	IS	GlaxoSmithKline Biologicals SA	20 Sep 2007
Anus Neoplasms	LI	GlaxoSmithKline Biologicals SA	20 Sep 2007
Anus Neoplasms	NO	GlaxoSmithKline Biologicals SA	20 Sep 2007
Human Papillomavirus Infection	EU	GlaxoSmithKline Biologicals SA	20 Sep 2007
Human Papillomavirus Infection	IS	GlaxoSmithKline Biologicals SA	20 Sep 2007
Human Papillomavirus Infection	LI	GlaxoSmithKline Biologicals SA	20 Sep 2007
Human Papillomavirus Infection	NO	GlaxoSmithKline Biologicals SA	20 Sep 2007
Human Papillomavirus-Related Cervical Carcinoma	EU	GlaxoSmithKline Biologicals SA	20 Sep 2007
Human Papillomavirus-Related Cervical Carcinoma	IS	GlaxoSmithKline Biologicals SA	20 Sep 2007
Human Papillomavirus-Related Cervical Carcinoma	LI	GlaxoSmithKline Biologicals SA	20 Sep 2007
Human Papillomavirus-Related Cervical Carcinoma	NO	GlaxoSmithKline Biologicals SA	20 Sep 2007

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Adenocarcinoma in Situ	Phase 3	CN	GlaxoSmithKline (China) Investment Co., Ltd.	28 Feb 2018
Adenocarcinoma in Situ	Phase 3	CN	GlaxoSmithKline Biologicals SA	28 Feb 2018
Hepatitis A	Phase 3	-	GSK Plc	01 Feb 2015
Meningococcal Infections	Phase 3	DO	GSK Plc	11 Jan 2013
Meningococcal Infections	Phase 3	EE	GSK Plc	11 Jan 2013
Meningococcal Infections	Phase 3	TH	GSK Plc	11 Jan 2013
Chronic human papillomavirus (HPV) infection	Phase 3	SN	GSK Plc	01 Oct 2007
Chronic human papillomavirus (HPV) infection	Phase 3	TZ	GSK Plc	01 Oct 2007
Cervical Intraepithelial Neoplasia	Phase 3	CO	GSK Plc	01 Oct 2005
Cervical Intraepithelial Neoplasia	Phase 3	DE	GSK Plc	01 Oct 2005

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03629886 (HPV-092, CTgov)	Phase 4	Cervical Intraepithelial Neoplasia	6,051	HPV (Types 16, 18) Vaccine, Adsorbed (Vacc-092 Group)	ojzndshpwl(esdiutqlaj) = gekxxakmls wsuzymsual (pnbarpbkhm, tloiiilqwo - qjzliofgnd) View more	-	19 Dec 2020
				HPV vaccine (Vacc-039 Group)	eqosflvzsh(hwbecuvazx) = tidwhgupsw tmlbwcwcue (gykavcykzm, otoplgxyjo - woqdwgffby) View more
NCT02979535 (CTgov)	Phase 3	Human Papillomavirus Infection \| Severe Dengue	480	CYD Dengue Vaccine+18] Vaccine, Recombinant (CYD Dengue Vaccine + Cervarix (Concomitant Administration))	ljdhxnpepl(mhckxkvsmy) = gotkotjfio csoorhburm (tklepdygjk, klaapuuuct - tbdgvpppzy) View more	-	09 Mar 2020
				CYD Dengue Vaccine+18] Vaccine, Recombinant (CYD Dengue Vaccine + Cervarix (Sequential Administration))	ljdhxnpepl(mhckxkvsmy) = gkcvgxcath csoorhburm (tklepdygjk, kdfwkxslau - fejaxtdvxb) View more
NCT00231413 (CTgov)	Phase 2	Human Papillomavirus Infection	383	HPV 16/18 L1 AS04 (HPV-16/18 Group)	oigeixaabe(kkszzyafeg) = dphuyhnthl sqjjrktjft (ttrosbmjwv, tpiuxqefvx - yfvwdyyapd) View more	-	12 Dec 2019
				HPV-16/18/31/45 L1 AS04 Formulation 1 (HPV-TETRA A Group)	oigeixaabe(kkszzyafeg) = nneindngjq sqjjrktjft (ttrosbmjwv, naquxchxxj - rzjzjbqzko) View more
NCT01031069 (CTgov)	Phase 4	Human Papillomavirus Infection \| HIV Infections	873	GSK Biologicals' HPV vaccine 580299 (HIV+/Cervarix Group)	ymmbaqbnxu(nhutnmpljm) = nqyngqquzp cjoxgeluha (ngljvpbxyd, utcvpujyvs - noehvqncoa) View more	-	24 Jul 2019
				18) Vaccine (Gardasil)+Merck's Human Papillomavirus Quadrivalent (Types 6, 11, 16, (HIV+/Gardasil Group)	ymmbaqbnxu(nhutnmpljm) = grcwpcpxkk cjoxgeluha (ngljvpbxyd, vcoygikjaf - nfxdwbphio) View more
NCT01190189 (CTgov)	Phase 3	Human Papillomavirus Infection	137	GSK580299 (Cervarix)	hpiorbmazo(ernvfvexrl) = heypmvezjh siannceekx (hsijobtncw, xorpnnhgka - paobjipgmy) View more	-	17 Dec 2018
NCT01190176 (CTgov)	Phase 3	Human Papillomavirus Infection	34	Placebo control+Cervarix	mmgozrkyfj(fbhqodkoih) = mvbepzoouc ahrpeuhpjn (szzlqvobdr, tbmfjlpkam - ryyfertlgm) View more	-	17 Oct 2018
NCT01249365 (CTgov)	Phase 3	Human Papillomavirus Infection	199	GSK580299 (Cervarix)	yhgdntnonp(rdhegmvlbf) = trbestbfkt lbbgtngval (qkksczcigt, rhljyrknnf - khwheomgwa) View more	-	16 Jul 2018
NCT01755689 (CTgov)	Phase 3	Meningococcal Infections	1,300	Cervarix®+Meningococcal vaccine GSK134612 (Nimenrix+Cervarix (1,2,7-Month) Group)	chpxxaydyu(wcttmdvwgn) = cvalcuyrgd pllyjpwuwb (lrbrdxtcqv, yvubvpfhjn - bdbhctmrnu) View more	-	03 Jul 2018
				Cervarix®+Meningococcal vaccine GSK134612 (Nimenrix+Cervarix (0,1,6-Month) Group)	chpxxaydyu(wcttmdvwgn) = aklmhqdwvg pllyjpwuwb (lrbrdxtcqv, agywzneujm - hmwqcnolso) View more
NCT01101542 (Pubmed \| Pharmacoepidemiol Drug Saf)	Not Applicable	Human Papillomavirus Infection \| Uterine Cervical Cancer	3,084	HPV-16/18 AS04-adjuvanted vaccine	zpblwizjcn(wxoeuwwccv) = Dysmenorrhoea was the most common unexpected AE reported by 30 subjects (1.0% [95%CI: 0.7-1.4]). ditorwjyja (iuqbcbxuws ) View more	-	01 Jul 2017
NCT00250276 (CTgov)	Phase 3	Human Papillomavirus Infection	798	Cervarix™ (Cervarix Lot1 Group)	zwgtpderck(weocblhzfa) = kvekodlefi cyvlhzdmdk (uvqsjhxwhn, uenaagabds - dwrumtdext) View more	-	17 Mar 2017
				Cervarix™ (Cervarix Lot2 Group)	zwgtpderck(weocblhzfa) = kvromfaloe cyvlhzdmdk (uvqsjhxwhn, vsdohdvtvy - wmwxievjht) View more